BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27693448)

  • 1. PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy.
    Guedes LB; Tosoian JJ; Hicks J; Ross AE; Lotan TL
    J Urol; 2017 Apr; 197(4):1054-1059. PubMed ID: 27693448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.
    Lotan TL; Carvalho FL; Peskoe SB; Hicks JL; Good J; Fedor H; Humphreys E; Han M; Platz EA; Squire JA; De Marzo AM; Berman DM
    Mod Pathol; 2015 Jan; 28(1):128-137. PubMed ID: 24993522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
    Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
    Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score.
    Fine SW; Epstein JI
    J Urol; 2008 Apr; 179(4):1335-8; discussion 1338-9. PubMed ID: 18289601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
    Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
    Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.
    Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW; Veltri RW
    Urology; 2009 May; 73(5):1092-7. PubMed ID: 19193410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Rate of Phosphatase and Tensin (PTEN) Gene Expression Loss in Prostate Cancer and its Link to Tumor Upgrading.
    Gharib A; Aziminejad A; Pourmotahari F; Kazeminejad B; Soleimani M
    Urol J; 2023 Dec; 20(6):403-407. PubMed ID: 36840446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies.
    Salles DC; Vidotto T; Faisal FA; Tosoian JJ; Guedes LB; Muranyi A; Bai I; Singh S; Yan D; Shanmugam K; Lotan TL
    J Mol Diagn; 2021 Aug; 23(8):1030-1041. PubMed ID: 34062284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.
    Trock BJ; Fedor H; Gurel B; Jenkins RB; Knudsen BS; Fine SW; Said JW; Carter HB; Lotan TL; De Marzo AM
    Mod Pathol; 2016 Jul; 29(7):764-71. PubMed ID: 27080984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage.
    Poulakis V; Witzsch U; De Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    J Urol; 2004 Oct; 172(4 Pt 1):1306-10. PubMed ID: 15371829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis.
    Ellis CL; Partin AW; Han M; Epstein JI
    J Urol; 2013 Dec; 190(6):2068-73. PubMed ID: 23727307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
    Bokhorst LP; Roobol MJ; Bangma CH; van Leenders GJ
    Prostate; 2017 Jul; 77(10):1137-1143. PubMed ID: 28543353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.
    Tosoian JJ; JohnBull E; Trock BJ; Landis P; Epstein JI; Partin AW; Walsh PC; Carter HB
    J Urol; 2013 Oct; 190(4):1218-22. PubMed ID: 23643603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.